EMEA fees to rise sharply
Pharmaceutical companies will have to brace themselves for large increases to fees charged by the European Agency for the Evaluation of Medicinal Products (EMEA), after its standing committees on medicinal products issued formal amendments to its charging regime for approval by the European Commission.
Pharmaceutical companies will have to brace themselves for large increases to fees charged by the European Agency for the Evaluation of Medicinal Products (EMEA), after its standing committees on medicinal products issued formal amendments to its charging regime for approval by the European Commission.
It has been asked to raise EMEA's annual fees by 26% and all other fees by 16%. These increases would cover veterinary as well as human medicine assessments. EMEA's services do not come cheap: the new increased fees would range as high as €232,000. They will come into force as soon as they are published in the European Union Official Journal.